Last reviewed · How we verify
Stem cell donation
At a glance
| Generic name | Stem cell donation |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Peer Education on Stem Cell Donation in Nursing Students (NA)
- Delayed Tolerance Through Mixed Chimerism (PHASE1, PHASE2)
- Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
- Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (PHASE3)
- Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
- Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
- Psychological Impact of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation on Donors (NA)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stem cell donation CI brief — competitive landscape report
- Stem cell donation updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI